Between June 1985 and November 1988, 30 patients with advanced stage, intermediate and high- grade non-Hodgkin's lymphoma were treated with a COPBLAM regimen including cyclophos- phamide, oncovin, prednisolone, bleomycin, adriamycin, procarbazine. Median age was 50.1 years and 10 patients were 60 years or old. 15 patients (50%) achieved a complete response (CR) and 10 patients (30%) had a partial response. Of the 15 CRs, 6 patients (40%) suffered a relapse. 3-year survival was 48.2% and disease-free survival for CRs was 54.5% with a median follow-up of 16.5 months. Constitutional symptoms were negatively associated with response rate and survival but not in disease free survival. Prognostic significance of age, histologic type, stage, and serum LDH were not demonstrated. Overall toxicity was acceptible without any treatment-related deaths. The incidenca of nonfatal infection was 16.7.